肝纤维化进程中细胞外基质对肝星状细胞的作用及机制研究进展*

doi:10.3969/j.issn.1672-5069.2017.03.037

摘要/Abstract

摘要： 肝纤维化是一种肝内弥漫性细胞外基质（ECM）过度沉积的病理过程,且肝星状细胞（HSC）的激活是肝纤维化发生发展的中心环节。本文主要介绍了在肝纤维化进程中ECM各种成分比例、分子结构的改变及其ECM分子空间结构改变对HSC的激活、增殖和凋亡的作用和机制。

关键词: 肝纤维化, 细胞外基质, 肝星状细胞

Abstract: Liver fibrosis is a pathological process characterized by intrahepatic diffuse excess deposition of extracellular matrix（ECM）,and hepatic stellate cells （HSC） activation. This article mainly reviewed the changes of various components of ECM,the molecular structure and the spatial structure of the ECM in the process of hepatic fibrosis. And we also summarized the mechanism by which the effects of these changes on the activation,proliferation and apoptosis of HSCs.

Key words: Liver fibrosis, Extracellular matrix, Hepatic stellate cell

秦雨萌, 陈胜华. 肝纤维化进程中细胞外基质对肝星状细胞的作用及机制研究进展^*[J]. 实用肝脏病杂志, 2017, 20(3): 381-384.

Qin Yumeng, Chen Shenghua. Influence of extracellular matrix on hepatic stellate cells during liver fibrosis process[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 381-384.

参考文献

[1] Duval F,Moreno-Cuevas JE,González-Garza MT,et al.Liver fibrosis and mechanisms of the protective action of medicinal plants targeting inflammation and the immune response. Int J Inflam,2015,20(5):943-957.
[2] 胡烨,张国. 肝纤维化的药物治疗研究进展. 实用肝脏病杂志,2016,19(1):8-11.
[3] 汪美凤,平键. 肝星状细胞主要信号转导通路与肝纤维化的关系. 实用肝脏病杂志,2010,13(6):466-469.
[4] Badylak SF,Taylor D,Uygun K.Whole-organ tissue engineering: decellularization and recellularization of three-dimensional matrix scaffolds. Annu Rev Biomed Eng, 2011,13(1): 27-53.
[5] Huang G,Greenspan DS.ECM roles in the function of metabolic tissues. Trends Endocrinol Metab,2012,23(1):16-22.
[6] Arnaoutova I,George J,Kleinman HK,et al.Basement membrane matrix (bme) has multiple uses with stem cells. Stem Cell Rev,2012,8(1):163-169.
[7] Reponen P,Sahlberg C,Munaut C,et al.High expression of 92-kd type IV collagenase(gelatinase b) in the osteoclast lineage during mouse development. J Cell Biol,1994,124(6):1091-1102.
[8] Milani S,Herbst H,Schuppan D,et al.In situ hybridization for procollagen types I,III and IV mRNA in normal and fibrotic rat liver:evidence for predominant expression in nonparenchymal liver cells. Hepatology,1989,10(1):84-92.
[9] Novo E,Cannito S,Morello E,et al.Hepatic myofibroblasts and fibrogenic progression of chronic liver diseases. Histol Histopathol,2015,30(9):1011-1032.
[10] Friedman SL.Hepatic stellate cells:protean,multifunctional,and enigmatic cells of the liver. Physiol Rev,2008,88(1):125-172.
[11] Friedman SL.Mechanisms of hepatic fibrogenesis. Gastroenterology,2008,134(6):1655-1669.
[12] Lu N,Liu Y,Tang A,et al.Hepatocyte-specific ablation of pp2a catalytic subunit α attenuates liver fibrosis progression via tgf-β1/smad signaling. Biomed Res Int,2015,15(2):794-803.
[13] Seyer JM,Hutcheson ET,Kang AH.Collagen polymorphism in normal and cirrhotic human liver. J Clin Inves,1977,59(2):241-248.
[14] Priya S,Sudhakaran PR.Cell survival,activation and apoptosis of hepatic stellate cells:modulation by extracellular matrix proteins. Hepatol Res,2008,38(12):1221-1232.
[15] Martin IV,Borkham-Kamphorst E,Zok S,et al.Platelet-derived growth factor (pdgf)-c neutralization reveals differential roles of pdgf receptors in liver and kidney fibrosis. Am J Pathol,2013,182(1):107-117.
[16] Kawelke N,Vasel M,Sens C,et al.Fibronectin protects from excessive liver fibrosis by modulating the availability of and responsiveness of stellate cells to active tgf-β. PLoS One,2011,6(11): 281-292.
[17] Qian J,Niu M,Zhai X,et al.β-Catenin pathway is required for tgf-β1 inhibition of pparγ expression in cultured hepatic stellate cells. Pharmacol Res,2012,66(3):219-225.
[18] Aziz-Seible RS,Lee SM,Kharbanda KK,et al.Ethanol feeding potentiates the pro-inflammatory response of kupffer cells to cellular fibronectin. Alcohol Clin Exp Res,2011,35(4):717-725.
[19] Zheng L,Chu J,Shi Y,et al.Bone marrow-derived stem cells ameliorate hepatic fibrosis by down-regulating interleukin-17. Cell Biosci,2013,3(1):46.
[20] Olsen AL,Sackey BK,Marcinkiewicz C,et al.Fibronectin extra domain-a promotes hepatic stellate cell motility but not differentiation into myofibroblasts. Gastroenterology,2012,142(4):928-937.
[21] Kim SH,Turnbull J,Guimond S.Extracellular matrix and cell signalling:the dynamic cooperation of integrin,proteoglycan and growth factor receptor. J Endocrinol,2011,209(2):139-151.
[22] Krishnan A,Li X,Kao WY,et al.Lumican,an extracellular matrix proteoglycan,is a novel requisite for hepatic fibrosis. Lab Invest,2012,92(12):1712-1725.
[23] Lauder RM.Chondroitin sulphate:a complex molecule with potential impacts on a wide range of biological systems. Complement Ther Med,2009,17(1):56-62.
[24] Campo GM,Avenoso A,Campo S,et al.The antioxidant activity of chondroitin-4-sulphate,in carbon tetrachloride-induced acute hepatitis in mice,involves nf-kappab and caspase activation. Br J Pharmacol,2008,155(6):945-956.
[25] Otranto M,Sarrazy V,Bonté F,et al.The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr,2012,6(3):203-219.
[26] 陈国忠,姜海行,陆正峰,等. 骨髓间充质干细胞共培养对肝星状细胞增殖、凋亡和RohA表达的调控. 世界华人消化杂志,2010,16(3):1643-1649.
[27] 张君红,姜海行,覃山羽,等. 肝细胞生长因子在TRAIL促进原代肝星状细胞凋亡中的作用. 中国老年学杂志,2013,10(23):5909-5911.
[28] 丁宁. 肝纤维化形成机制的研究进展. 临床肝胆病杂志,2009,25(1):73-77.
[29] Oliveira CL,Bates JH,Suki B.A network model of correlated growth of tissue stiffening in pulmonary fibrosis. New J Phys,2014,16(6): 65-83.
[30] Tiruvannamalai-Annamalai R,Armant DR,Matthew HW.A glycosaminoglycan based,modular tissue scaffold system for rapid assembly of perfusable,high cell density,engineered tissues. PLoS One,2014,9(1):842-857.
[31] Wang PP,Xie DY,Liang XJ,et al.HGF and direct mesenchymal stem cells contact synergize to inhibit hepatic stellate cells activation through TLR4/NF-kB pathway. PLoS One,2012,7(8):434-448.
[32] 施启鹏,郭圆圆,周晗,等. 间充质干细胞移植后抑制肝星状细胞活化减轻肝纤维化. 南京医科大学学报(自然科学版),2015,2(7):981-987.
[33] 刘卫英,肖琳,张泽高,等. 乙型肝炎和肝硬化患者血清血管紧张素系统的变化及其与肝纤维化的关系. 实用肝脏病杂志,2014,17(4):352-355.
[34] Nakamura I,Zakharia K,Banini BA,et al.Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of fgf,vegf and pdgf signaling. PLoS One,2014,9(4):922-933.
[35] Thabut D,Shah V.Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease:new targets for the treatment of portal hypertension. J Hepatol,2010,53(5):976-980.
[36] Novo E,Cannito S,Zamara E,et al.Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol,2007,170(6):1942-1953.
[37] Coulon S,Heindryckx F,Geerts A,et al.Angiogenesis in chronic liver disease and its complications. Liver Int,2011,31(2):146-162.
[38] Zhang F,Kong D,Chen L,et al.Peroxisome proliferator-activated receptor-γ interrupts angiogenic signal transduction by transrepression of platelet-derived growth factor-β receptor in hepatic stellate cells. J Cell,2014,127(2):305-314.

肝纤维化进程中细胞外基质对肝星状细胞的作用及机制研究进展^*

Influence of extracellular matrix on hepatic stellate cells during liver fibrosis process

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[2]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[3]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[4]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[5]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[6]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[7]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[8]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.
[9]	周丽云, 李校天, 李丽, 杨俊超. 1,25（OH）₂D₃通过调节miR-146a水平抑制大鼠肝纤维化的体内和体外观察[J]. 实用肝脏病杂志, 2019, 22(3): 333-336.
[10]	吴亚平,周冰清,蒋蓓莉. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 196-199.
[11]	玉苏甫·吐尔逊, 赵燕霞. 小剂量二乙基亚硝胺诱导大鼠肝纤维化模型的建立[J]. 实用肝脏病杂志, 2019, 22(1): 33-36.
[12]	郭晓霞, 郭琲婷, 孔祥璐. 脾切除对原发性胆汁性肝硬化小鼠肝组织纤维化影响研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 837-841.
[13]	刘恩强, 陈果, 廖修用, 许美凤, 魏贵玉, 罗小平. 虾青素对肝纤维化大鼠的保护作用及机制研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 842-846.
[14]	黄春明, 杨湛, 聂玉强, 胡中伟, 周永健, 詹远京, 郭家伟, 余卫华. γ-谷氨酰转肽酶/血小板比值对血清转氨酶正常的慢性HBV感染者肝纤维化的预测价值分析^*[J]. 实用肝脏病杂志, 2018, 21(6): 859-862.
[15]	潘高峰综述, 傅茂英, 郜玉峰审校. 内质网应激与肝纤维化关系研究进展^*[J]. 实用肝脏病杂志, 2018, 21(6): 987-990.